Genes that negatively interact with both TSC1 and TSC2 represent potential therapeutic targets (i.e. drugs inhibiting a negative interactor would be predicted to suppress the growth of tumor cells while leaving phenotypically normal cells unaffected). This evidence concerns the gene TSC1 and neoplasm.